08.29.12
Andrew Kelley has been appointed chief operating officer of NextPharma Technologies and Pierre Delavaud has been appointed executive vice president sales and marketing. Also, Matthew Wilder has been appointed vice president U.S. sales and marketing.
Mr. Kelley has more than 27 years of experience in the pharmaceutical industry. Most recently, he led manufacturing operations at Patheon. Mr. Delavaud joins the company from SkyePharma, and previously spent 14 years at Catalent, where he held various senior positions. Mr. Wilder has more than 10 years of sales and marketing experience in the U.S. pharmaceutical industry and joins the company from Sanofi Pharmaceuticals, where he held various senior positions.
Franck Latrille, chief executive officer, NextPharma, said, “We are delighted to welcome our three new colleagues to our growing team at NextPharma. This is an exciting time for the company, and we are confident that with the injection of their expertise to the team, we can continue to improve our business offerings.”
Mr. Kelley has more than 27 years of experience in the pharmaceutical industry. Most recently, he led manufacturing operations at Patheon. Mr. Delavaud joins the company from SkyePharma, and previously spent 14 years at Catalent, where he held various senior positions. Mr. Wilder has more than 10 years of sales and marketing experience in the U.S. pharmaceutical industry and joins the company from Sanofi Pharmaceuticals, where he held various senior positions.
Franck Latrille, chief executive officer, NextPharma, said, “We are delighted to welcome our three new colleagues to our growing team at NextPharma. This is an exciting time for the company, and we are confident that with the injection of their expertise to the team, we can continue to improve our business offerings.”